TY  - JOUR 
AU  - Escribá, Pablo V
AU  - Gil-Agudo, Ángel M
AU  - Vidal Samsó, Joan
AU  - Sánchez-Raya, Judith
AU  - Salvador-de la Barrera, Sebastián
AU  - Soto-León, Vanesa
AU  - León-Álvarez, Natacha
AU  - Méndez Ferrer, Bosco
AU  - Membrilla-Mesa, Miguel David
AU  - Redondo Galán, Carolina
AU  - Benito-Penalva, Jesús
AU  - Montoto-Marqués, Antonio
AU  - Medel Rebollo, Javier
AU  - Palazón García, Ramiro
AU  - Gutiérrez Henares, Francisco
AU  - Miralles, Marc
AU  - Torres, Manuel
AU  - Nieto Librero, Ana Belén
AU  - García Marco, David
AU  - Gómez, Carmela
AU  - Jimeno, David
AU  - Oliviero, Antonio
PY  - 2024
SN  - 1362-4393
UR  - http://hdl.handle.net/10366/161913
AB  - [EN]Double-blind, randomized, placebo-controlled, parallel-group multicentric phase IIA clinical trial.
To assess the safety and tolerability of oral administration of NFX-88 in subjects with chronic spinal cord injury (SCI) and explore its efficacy...
LA  - eng
PB  - Springer Nature
KW  - Analgesics
KW  - Pain Measurement
KW  - Spinal Cord Injuries
KW  - Aged
KW  - Young Adult
KW  - Adult
KW  - Treatment Outcome
KW  - Humans
KW  - Neuralgia
KW  - Middle Aged
KW  - Double-Blind Method
TI  - Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury.
DO  - 10.1038/s41393-024-01006-4
T2  - Spinal Cord
VL  - 62
M2  - 454
ER  -